🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

19May: What is Illumina demanding of Element Biosciences in a patent infringement lawsuit filed Thursday? And how is Element responding to $ILMN's allegations? Read about the case in my latest for Genetic Engineering & Biotechnology News: genengnews.com/topics/omics/i…

19May: How much did 10x Genomics disclose it will receive from Bruker and Vizgen in settlements of separate lawsuits? I join colleague and editor Julianna LeMieux PhD to recap the settlements, in our latest for Genetic Engineering & Biotechnology News: genengnews.com/topics/omics/1…

19May: What opportunities, and risks, do analysts see in BioMarin 's planned acquisition of Inozyme Pharma ? Read about $BMRN and $INZY, plus updates on $BLUE, $SEPN, and $URGN in my latest StockWatch for Genetic Engineering & Biotechnology News: genengnews.com/topics/drug-di…

19May: What a day for news... What steps remain before the bankruptcy court signs off on Regeneron's $256M acquisition of 23andMe? Details in Genetic Engineering & Biotechnology News: genengnews.com/topics/omics/r…

Don't Miss Alex Philippidis Latest StockWatch! With Inozyme Pharma buyout, BioMarin pursues growth via M&A. Pluse bluebird bio shares jumped; @Septerna_Inc shares leaped; and UroGen Pharma shares tumbled. #StockMarket Alex Philippidis hubs.li/Q03n7FDl0

SundayBest (Kontakion of Sunday of the Blind Man, Plagal of the First Tone): I come to You, O Christ, as the man blind from birth. With the eyes of my soul blinded, I cry out to You in repentance, "You are the resplendent Light of those in darkness."

🎧 Customized CRISPR for KJ, 10x Genomics and Illumina Lawsuits, Regeneron Bags 23andMe In the latest episode of Touching Base, we discuss big news in #CRISPR along with business updates. Fay Lin, PhD Uduak Thomas Alex Philippidis Corinna Singleman hubs.li/Q03nSczk0

🎧 Don't miss he latest podcast episode of Touching Base! Customized CRISPR for KJ, 10x Genomics and Illumina Lawsuits, Regeneron Bags 23andMe ASGCT Bruker Vizgen Element Biosciences Prime Medicine Uduak Thomas Alex Philippidis Fay Lin, PhD hubs.li/Q03pdkN-0

28May: What does Rocket Pharmaceuticals suspect may have led to the death of a patient dosed with its Danon disease gene therapy candidate RP-A501 in a pivotal trial? And how did three analysts respond to the news? My latest for Genetic Engineering & Biotechnology News: genengnews.com/topics/genome-…

SundayBest (Psalm 143: 6-7, in Sunday Orthros): I spread out my hands to you; my soul longs for you like a thirsty land. Lord, hear me quickly; my spirit fails.

2June: How did @Sanofi CEO Paul Hudson describe his company's capacity for additional acquisitions after agreeing to buy Blueprint Medicines for up to $9.5B? My latest for Genetic Engineering & Biotechnology News: genengnews.com/topics/drug-di…

First Personalized CRISPR Gene Editing Therapy Patient Baby KJ Discharged — excellent piece by Jonathan D. Grinstein, PhD on the latest milestone for the baby who made gene editing history insideprecisionmedicine.com/topics/precisi… via Inside Precision Medicine

See why we are excited about the potential ABS-101, Absci’s first AI-designed biologic to enter the clinic, has to treat IBD, and get an update on some of the other assets in our growing pipeline in this deep dive with Genetic Engineering & Biotechnology News's Alex Philippidis. #AI #DrugDiscovery #Biologics

Cell and Gene Therapy Leaders Tell FDA: “Believe in American Solutions” — Kevin Davies & Alex Philippidis report on today’s huge roundtable session with U.S. FDA leadership. genengnews.com/topics/genome-… via Genetic Engineering & Biotechnology News

Genetic Engineering & Biotechnology News Kevin Davies Alex Philippidis U.S. FDA Impressive FDA dialogue opens doors to international collaboration. Trust in local innovation is crucial while leveraging global ties for cell and gene therapy advancements.

6June: Hear about the latest patient death in a gene therapy trial, the Boltz-2 open-source tool & more from Genetic Engineering & Biotechnology News colleagues Corinna Singleman, Fay Lin, PhD, Uduak Thomas & me on this latest episode of our "Touching Base" podcast. Download & listen: genengnews.com/multimedia/pod…

🎧GEN's New Episode of Touching Base Is Available! GEN’s @alexwestchester, Fay Lin, PhD, Uduak Thomas, and Corinna Singleman highlight standout GEN coverage. #podcast #ArtificialIntelligence #aging #immunotherapy hubs.li/Q03r75MX0

SundayBest (Apolytikion of Pentecost, Plagal of the Fourth Tone): Blessed are You, O Christ our God, who made fishermen all-wise, sending upon them the Holy Spirit and, through them, netting the world. O Loving One, glory to You.

9June: What factors would appear to make MoonLake Immunotherapeutics (NASDAQ: MLTX) a potential attractive acquisition for Merck? Read about the reported $3B+ deal in the works, plus updates on $LIMN, $LYRA, $PHAT, and $MEHCO in my latest StockWatch for Genetic Engineering & Biotechnology News: genengnews.com/topics/drug-di…